Increasing R&D by the Pharma Companies for New Drug Development is Surging the Market Growth
The increasing R&D by the pharma companies for new drug development,
high prevalence of colorectal cancer, rising government initiative to
create awareness among people along with escalating investment by the
market players to develop early detection of test kit are some of the
major factors projected to fuel the growth of China Colorectal cancer market.
Colorectal cancer (CRC) is a major public health concern as it is among
the third most common cancer in China after lung cancer. Moreover,
surging government initiative by launching various awareness campaign on
colorectal cancer, escalating late-stage pipeline therapies and launch
of angiogenesis inhibitors by the market player in China for the
treatment of colorectal cancer are proliferating the growth of the
market in the coming years.
The key players with a considerable market share in the China Colorectal Cancer market are Amgen China, Bristol-Myers Squibb, Bayer AG, Merck KGaA, Roche (china) Co., Ltd., Eli Lilly and Company, Sanofi China, Taiho Pharmaceutical, Novartis AG, Pfizer Inc. etc.
Comments
Post a Comment